AU2010301675B2 - Novel phenol derivative - Google Patents

Novel phenol derivative Download PDF

Info

Publication number
AU2010301675B2
AU2010301675B2 AU2010301675A AU2010301675A AU2010301675B2 AU 2010301675 B2 AU2010301675 B2 AU 2010301675B2 AU 2010301675 A AU2010301675 A AU 2010301675A AU 2010301675 A AU2010301675 A AU 2010301675A AU 2010301675 B2 AU2010301675 B2 AU 2010301675B2
Authority
AU
Australia
Prior art keywords
added
mixture
group
distilled
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010301675A
Other languages
English (en)
Other versions
AU2010301675A1 (en
Inventor
Naoki Ashizawa
Tsutomu Inoue
Takashi Iwanaga
Seiichi Kobashi
Koji Matsumoto
Sachiho Miyata
Osamu Nagata
Tetsuya Taniguchi
Junichiro Uda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Yakuhin Co Ltd
Original Assignee
Fuji Yakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43826265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010301675(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fuji Yakuhin Co Ltd filed Critical Fuji Yakuhin Co Ltd
Publication of AU2010301675A1 publication Critical patent/AU2010301675A1/en
Application granted granted Critical
Publication of AU2010301675B2 publication Critical patent/AU2010301675B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2010301675A 2009-09-30 2010-09-29 Novel phenol derivative Active AU2010301675B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009-227402 2009-09-30
JP2009227402A JP5325065B2 (ja) 2009-09-30 2009-09-30 新規フェノール誘導体
PCT/JP2010/066925 WO2011040449A1 (ja) 2009-09-30 2010-09-29 新規フェノール誘導体

Publications (2)

Publication Number Publication Date
AU2010301675A1 AU2010301675A1 (en) 2012-04-05
AU2010301675B2 true AU2010301675B2 (en) 2013-08-22

Family

ID=43826265

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010301675A Active AU2010301675B2 (en) 2009-09-30 2010-09-29 Novel phenol derivative

Country Status (23)

Country Link
US (1) US8367843B2 (enExample)
EP (1) EP2484669B1 (enExample)
JP (1) JP5325065B2 (enExample)
KR (1) KR101647174B1 (enExample)
CN (1) CN102639518B (enExample)
AU (1) AU2010301675B2 (enExample)
BR (1) BR112012007069B1 (enExample)
CA (1) CA2775309C (enExample)
DK (1) DK2484669T3 (enExample)
ES (1) ES2549603T3 (enExample)
HU (1) HUE026007T2 (enExample)
IL (1) IL218519A (enExample)
IN (1) IN2012DN02551A (enExample)
MX (1) MX2012003392A (enExample)
MY (1) MY160394A (enExample)
NZ (1) NZ598582A (enExample)
PH (1) PH12012500643A1 (enExample)
PL (1) PL2484669T3 (enExample)
PT (1) PT2484669E (enExample)
RU (1) RU2536689C2 (enExample)
TW (1) TWI461195B (enExample)
WO (1) WO2011040449A1 (enExample)
ZA (1) ZA201201895B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5851802B2 (ja) 2011-03-30 2016-02-03 富士重工業株式会社 炭素繊維強化樹脂複合材用ドリル
WO2015191034A1 (en) * 2014-06-09 2015-12-17 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
WO2017038799A1 (ja) * 2015-09-04 2017-03-09 サントリーホールディングス株式会社 ウレアーゼ活性阻害剤
HUE051448T2 (hu) * 2015-09-10 2021-03-01 Jiangsu Atom Bioscience Imidazo[1,2a]piridinek hiperurikémia vagy köszvény kezelésére vagy megelõzésére
CN105675557B (zh) * 2016-01-07 2019-01-25 济南大学 基于苯炔荧光试剂检测硫脲含量的新方法
EP3957629B1 (en) 2016-07-18 2023-09-06 Arthrosi Therapeutics, Inc. Process for making deuterated hydroxy-benzbromarone and intermediates thereof
BR112019018840B1 (pt) 2017-04-28 2023-12-19 Fuji Yakuhin Co., Ltd Forma cristalina de 3-(3,5-dicloro-4-hidroxibenzoil)-1,1-dioxo-2,3-dihidro 1,3 -benzotiazol
CN109928890B (zh) * 2017-12-15 2021-11-09 重庆常捷医药有限公司 一种托伐普坦中间体2-甲基-4-n-(2-甲基苯甲酰)苯甲酸的制备方法
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
KR20210100677A (ko) 2018-12-06 2021-08-17 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
EP4074313A4 (en) * 2019-12-09 2024-01-03 Fuji Yakuhin Co., Ltd. SOLID PHARMACEUTICAL PREPARATION
CN111662247A (zh) * 2020-07-17 2020-09-15 苏州明锐医药科技有限公司 一种多替诺德的合成方法
CN111675675A (zh) * 2020-07-17 2020-09-18 苏州明锐医药科技有限公司 多替诺德的制备方法
CN112430221B (zh) * 2020-11-20 2023-06-23 成都诺和晟泰生物科技有限公司 用于预防、治疗或减轻高尿酸血症或痛风的化合物及其应用
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN114903879B (zh) * 2022-06-23 2023-10-31 东北大学 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途
CN115160314B (zh) * 2022-07-28 2023-12-05 南方医科大学 杂环芳酰胺类化合物及其制备方法和应用
WO2025085662A1 (en) 2023-10-17 2025-04-24 Vanderbilt University Compounds for tocolytic use
CN118580197A (zh) * 2023-11-16 2024-09-03 广东东阳光药业股份有限公司 一种多替诺雷制备方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057460A1 (ja) * 2004-11-29 2006-06-01 Japan Tobacco Inc. 窒素含有縮合環化合物及びその用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720683A (en) * 1970-09-02 1973-03-13 Squibb & Sons Inc 2-phenyl-3-acylbenzothiazolines and their oxides
US7521570B2 (en) 2004-06-10 2009-04-21 Torli Pharmaceutical Co., Ltd. Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof
JP3988832B2 (ja) 2004-11-29 2007-10-10 日本たばこ産業株式会社 窒素含有縮合環化合物及びその用途
EP1985297A1 (en) * 2006-01-27 2008-10-29 Japan Tobacco, Inc. Carboxylic acid compound and use thereof
US20080305169A1 (en) * 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
US20080064871A1 (en) * 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
WO2008062740A1 (fr) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Composé azoté à anneaux fusionnés et son utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006057460A1 (ja) * 2004-11-29 2006-06-01 Japan Tobacco Inc. 窒素含有縮合環化合物及びその用途

Also Published As

Publication number Publication date
NZ598582A (en) 2013-04-26
IL218519A (en) 2016-03-31
TW201121544A (en) 2011-07-01
ES2549603T3 (es) 2015-10-29
AU2010301675A1 (en) 2012-04-05
JP2011074017A (ja) 2011-04-14
CN102639518A (zh) 2012-08-15
EP2484669B1 (en) 2015-07-29
CA2775309A1 (en) 2011-04-07
US8367843B2 (en) 2013-02-05
HUE026007T2 (en) 2016-05-30
KR20120080183A (ko) 2012-07-16
RU2536689C2 (ru) 2014-12-27
MX2012003392A (es) 2012-04-10
TWI461195B (zh) 2014-11-21
KR101647174B1 (ko) 2016-08-09
MY160394A (en) 2017-03-15
HK1169650A1 (en) 2013-02-01
US20120184587A1 (en) 2012-07-19
CN102639518B (zh) 2015-03-25
ZA201201895B (en) 2013-09-25
IN2012DN02551A (enExample) 2015-08-28
PT2484669E (pt) 2015-10-30
DK2484669T3 (en) 2015-09-21
EP2484669A4 (en) 2013-02-27
IL218519A0 (en) 2012-07-31
JP5325065B2 (ja) 2013-10-23
PH12012500643A1 (en) 2012-11-12
BR112012007069A2 (pt) 2016-04-19
CA2775309C (en) 2017-12-12
EP2484669A1 (en) 2012-08-08
BR112012007069B1 (pt) 2020-03-03
WO2011040449A1 (ja) 2011-04-07
PL2484669T3 (pl) 2015-12-31
RU2012117786A (ru) 2013-11-10

Similar Documents

Publication Publication Date Title
AU2010301675B2 (en) Novel phenol derivative
JP6569792B2 (ja) ハロゲン置換へテロ環化合物
RU2733750C2 (ru) Производные карбоксизамещенных (гетеро)ароматических колец, способ их получения и применение
WO2007043457A1 (ja) トリアリールカルボン酸誘導体
TW201808909A (zh) 稠環衍生物、其製備方法、中間體、藥物組合物及應用
EP1419770A1 (en) Apo ai expression accelerating agent
CN102627638A (zh) 噻二唑取代的香豆素衍生物及其作为白三烯生物合成抑制剂的用途
CA2578168A1 (en) 2-phenylpyridine derivative
JPWO2006022375A1 (ja) ２−フェニルチオフェン誘導体
US20220289698A1 (en) Inhibitors of human atgl
HK1169650B (en) Novel phenol derivative
US20090029975A1 (en) 1,3-benzothiazinone derivative and use thereof
US20230121233A1 (en) Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same
WO2025252099A1 (zh) 一种吡咯并六元芳环化合物及其制备方法和应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)